Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Trimethylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL460230 | 1.00 | PTGS1 (0.36) | PTGS1AKR1C3FFAR3LCKFYN | |
| Trimethylammonium SCHEMBL27993313 | 1.00 | PTGS1 (0.36) | PTGS1AKR1C3FFAR3LCKFYN | |
| Trimethylammonium SCHEMBL1377988 | 0.97 | PTGS1 (0.37) | PTGS1AKR1C3FFAR3LCKFYN | |
| Trimethylammonium SCHEMBL1377985 | 0.97 | PTGS1 (0.37) | PTGS1AKR1C3FFAR3LCKFYN | |
| Trimethylammonium SCHEMBL141480 | 0.94 | PTGS1 (0.36) | PTGS1AKR1C3FFAR3LCKFYN | |
| Trimethylammonium SCHEMBL141479 | 0.94 | PTGS1 (0.36) | PTGS1AKR1C3FFAR3LCKFYN | |
| Bromide SCHEMBL27583888 | 0.91 | — | — | |
| SCHEMBL133954 | 0.87 | — | — | |
| SCHEMBL15042 | 0.87 | — | — | |
| SCHEMBL1396002 | 0.87 | FFAR3 (0.43) | PTGS1AKR1C3FFAR3LCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848336-B1 | METHOD FOR MANUFACTURING HOLLOW METAL NANOPARTICLES | LG CHEMICAL LTD (KR) | 2017-04-26 | — | — | EP | claimed |
| EP-2939764-A1 | METHOD FOR MANUFACTURING HOLLOW METAL NANOPARTICLE SUPPORTED BY SUPPORT BODY | LG Chem, Ltd. (KR) | 2015-11-04 | — | — | EP | claimed |
| US-20150118496-A1 | METHOD FOR FABRICATING HOLLOW METAL NANO PARTICLES AND HOLLOW METAL NANO PARTICLES FABRICATED BY THE METHOD | LG CHEM, LTD. (KR) | 2015-04-30 | — | — | US | claimed |
| US-8992660-B2 | Method for fabricating hollow metal nano particles and hollow metal nano particles fabricated by the method | LG CHEM, LTD. (KR) | 2015-03-31 | — | — | US | claimed |
| EP-2848336-A1 | METHOD FOR MANUFACTURING HOLLOW METAL NANOPARTICLES, AND HOLLOW METAL NANOPARTICLES MANUFACTURED THEREBY | LG Chem, Ltd. (KR) | 2015-03-18 | — | — | EP | claimed |
| US-20140308537-A1 | METHOD FOR FABRICATING HOLLOW METAL NANO PARTICLES AND HOLLOW METAL NANO PARTICLES FABRICATED BY THE METHOD | LG CHEM, LTD. (KR) | 2014-10-16 | — | — | US | claimed |
| US-20100266705-A1 | NANOPARTICULATE MEGESTROL FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. | 2010-10-21 | — | — | US | claimed |
| EP-1471887-B1 | NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | ELAN PHARMA INT LTD (IE) | 2010-04-21 | — | — | EP | claimed |
| EP-1853234-A2 | AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE | Elan Pharma International Limited (IE) | 2007-11-14 | — | — | EP | claimed |
| WO-2006088894-A2 | AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2006-08-24 | — | — | WO | claimed |
| US-20030185869-A1 | Having lysozyme adsorbed onto or associated with the surface of an active agent | ELAN PHARMA INTERNATIONAL LTD. | 2003-10-02 | — | — | US | claimed |
| EP-4308724-A1 | ISOTHERMAL AMPLIFICATION OF PATHOGENS | Becton, Dickinson and Company (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023150710-A1 | NON-OPAQUE LYTIC BUFFER COMPOSITION FORMULATIONS | BECTON, DICKINSON AND COMPANY (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150708-A1 | METHOD FOR SEPARATING GENOMIC DNA FOR AMPLIFICATION OF SHORT NUCLEIC ACID TARGETS | BECTON, DICKINSON AND COMPANY (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-110636837-B | Pharmaceutical composition of CYP17 inhibitor and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| US-20030108611-A1 | Bioadhesive nanoparticulate compositions having cationic surface stabilizers | ELAN PHARMA INTERNATIONAL LTD. | 2003-06-12 | — | — | US | disclosed |
| US-6428814-B1 | STABILIZERS PREVENT AGGREGATION OF NANOPARTICLES AND INCREASE BIOADHESION TO SUBSTRATES SUCH AS AN INSECT, TEETH, BONE, NAILS, CHITIN, FEATHERS, SCALES, MUCOUS, SKIN, HAIR, AND/OR PLANT TISSUE | ELAN PHARMA INTERNATIONAL LTD. (IL) | 2002-08-06 | — | — | US | disclosed |
| EP-1217993-A2 | BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS | Elan Pharma International Limited (IE) | 2002-07-03 | — | — | EP | disclosed |
| US-20020068092-A1 | BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS | ALKERMES, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2001026635-A2 | BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185869-A1 | Having lysozyme adsorbed onto or associated with the surface of an active agent | LPO, LCT, CTSA | PTGS1 3164/4885AKR1C3 1565/4885FFAR3 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.